NASDAQ:SLS SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free SLS Stock Alerts $1.01 -0.02 (-1.94%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.99▼$1.0350-Day Range$0.51▼$1.5552-Week Range$0.50▼$1.91Volume1.27 million shsAverage Volume1.83 million shsMarket Capitalization$32.38 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get SELLAS Life Sciences Group alerts: Email Address SELLAS Life Sciences Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside197.0% Upside$3.00 Price TargetShort InterestBearish16.16% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.71Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.04) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.84 out of 5 starsMedical Sector664th out of 938 stocksPharmaceutical Preparations Industry309th out of 433 stocks 3.5 Analyst's Opinion Consensus RatingSELLAS Life Sciences Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, SELLAS Life Sciences Group has a forecasted upside of 197.0% from its current price of $1.01.Amount of Analyst CoverageSELLAS Life Sciences Group has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.16% of the outstanding shares of SELLAS Life Sciences Group have been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently increased by 14.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSELLAS Life Sciences Group does not currently pay a dividend.Dividend GrowthSELLAS Life Sciences Group does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLS. Previous Next 3.7 News and Social Media Coverage News SentimentSELLAS Life Sciences Group has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for SELLAS Life Sciences Group this week, compared to 1 article on an average week.Search Interest13 people have searched for SLS on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.MarketBeat Follows4 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.60% of the stock of SELLAS Life Sciences Group is held by insiders.Percentage Held by InstitutionsOnly 17.38% of the stock of SELLAS Life Sciences Group is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for SELLAS Life Sciences Group are expected to grow in the coming year, from ($1.04) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of SELLAS Life Sciences Group is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SELLAS Life Sciences Group is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSELLAS Life Sciences Group has a P/B Ratio of 4.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About SELLAS Life Sciences Group Stock (NASDAQ:SLS)SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.Read More SLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLS Stock News HeadlinesMarch 28, 2024 | msn.comSELLAS Life Sciences Group files for $200M mixed shelfMarch 28, 2024 | globenewswire.comSELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate UpdateMarch 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. March 27, 2024 | markets.businessinsider.comBuy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened FinancialsMarch 26, 2024 | markets.businessinsider.comSELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL StudyMarch 26, 2024 | globenewswire.comSELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL StudyMarch 26, 2024 | americanbankingnews.comSELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 2.8%March 21, 2024 | wsj.comSELLAS Life Sciences Group Inc.March 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.March 19, 2024 | globenewswire.comSELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMarch 19, 2024 | globenewswire.comSELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ETMarch 16, 2024 | marketwatch.comSellas Life Sciences Shares Drop 31% After Direct Offering PricesMarch 15, 2024 | msn.comGeron, Graphite Bio, Immuneering among healthcare moversMarch 15, 2024 | msn.comSELLAS Life Sciences looks to raise $20M in a direct offeringMarch 15, 2024 | markets.businessinsider.comSellas Announces $20 Mln Registered Direct Offering, Concurrent Private PlacementMarch 15, 2024 | finance.yahoo.comSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMarch 15, 2024 | globenewswire.comSELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesMarch 12, 2024 | seekingalpha.comAadi Bioscience Q4 2023 Earnings PreviewMarch 10, 2024 | investing.comSellas Life Sciences Group Inc (SLS)March 9, 2024 | finanznachrichten.deSELLAS Life Sciences Group, Inc.: SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization PartnershipsMarch 8, 2024 | globenewswire.comSELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization PartnershipsMarch 7, 2024 | finance.yahoo.comSLS Mar 2024 4.000 putMarch 1, 2024 | finance.yahoo.comSELLAS Life Sciences Group, Inc. (SLS)March 1, 2024 | globenewswire.comSELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) ConferenceFebruary 29, 2024 | globenewswire.comSELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and TimeFebruary 22, 2024 | morningstar.comSELLAS Life Sciences Group IncFebruary 16, 2024 | ca.finance.yahoo.comSLS Feb 2024 0.500 callSee More Headlines Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SLS CUSIPN/A CIK1390478 Webwww.sellaslifesciences.com Phone(646) 200-5278Fax441-400-2875Employees17Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+197.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-805.32% Return on Assets-199.87% Debt Debt-to-Equity RatioN/A Current Ratio0.44 Quick Ratio0.44 Sales & Book Value Annual Sales$1 million Price / Sales32.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book4.39Miscellaneous Outstanding Shares32,062,000Free Float31,549,000Market Cap$32.38 million OptionableNot Optionable Beta2.35 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Angelos M. Stergiou M.D. (Age 48)ScD h.c., Founder, President, CEO & Director Comp: $921.99kKey CompetitorsTheratechnologiesNASDAQ:THTXeFFECTOR TherapeuticsNASDAQ:EFTRAcurx PharmaceuticalsNASDAQ:ACXPAcasti PharmaNASDAQ:ACSTBiora TherapeuticsNASDAQ:BIORView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 110,418 shares on 3/11/2024Ownership: 3.579%Virtu Financial LLCBought 40,952 shares on 2/26/2024Ownership: 0.187%Vanguard Group Inc.Bought 110,418 shares on 2/15/2024Ownership: 3.578%Citadel Advisors LLCSold 1,800 shares on 2/15/2024Ownership: 0.000%Northern Trust CorpBought 23,077 shares on 2/13/2024Ownership: 0.195%View All Institutional Transactions SLS Stock Analysis - Frequently Asked Questions Should I buy or sell SELLAS Life Sciences Group stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SELLAS Life Sciences Group in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLS shares. View SLS analyst ratings or view top-rated stocks. What is SELLAS Life Sciences Group's stock price target for 2024? 1 brokers have issued twelve-month price objectives for SELLAS Life Sciences Group's shares. Their SLS share price targets range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 197.0% from the stock's current price. View analysts price targets for SLS or view top-rated stocks among Wall Street analysts. How have SLS shares performed in 2024? SELLAS Life Sciences Group's stock was trading at $1.06 at the start of the year. Since then, SLS stock has decreased by 4.7% and is now trading at $1.01. View the best growth stocks for 2024 here. How were SELLAS Life Sciences Group's earnings last quarter? SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) released its quarterly earnings results on Friday, November, 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. When did SELLAS Life Sciences Group's stock split? SELLAS Life Sciences Group's stock reverse split on the morning of Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are SELLAS Life Sciences Group's major shareholders? SELLAS Life Sciences Group's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.58%), Vanguard Group Inc. (3.58%), Armistice Capital LLC (2.56%), Opus Capital Group LLC (0.42%), Northern Trust Corp (0.19%) and Virtu Financial LLC (0.19%). View institutional ownership trends. How do I buy shares of SELLAS Life Sciences Group? Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.